Get started
Author

Pharis Mohideen

Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes.
2000 · S E Nikoulina, T P Ciaraldi, et al. · Diabetes · 356
PDF
Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial
2017 · Julia K Prague, Rachel E Roberts, et al. · The Lancet · 204
PDF
Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial
2010 · S. Petersenn, J. Schopohl, et al. · The Journal of Clinical Endocrinology & Metabolism · 204
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
2012 · Larry K Kvols, Kjell E Oberg, et al. · Endocrine Related Cancer · 199
PDF
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial
2008 · C. Pan, W. Yang, et al. · Diabetic Medicine · 165
PDF
Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110β Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects
2002 · Young-Bum Kim, Theodore P. Ciaraldi, et al. · Diabetes · 129
Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
2006 · David M. Kendall, Cindy J. Rubin, et al. · Diabetes Care · 115
Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study
2021 · Christine G. Lee, Brandy Heckman-Stoddard, et al. · Diabetes Care · 102
Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action
2018 · Julia K. Prague, Rachel E. Roberts, et al. · Menopause The Journal of The North American Menopause Society · 94
35th Annual Meeting of the European Association for the Study of Diabetes
1999 · A. Melander, J. Olsson, et al. · Diabetologia · 86
Metformin‐glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy
2005 · A. Garber, E. Klein, et al. · Diabetes Obesity and Metabolism · 84
The Impact of Physical Activity on the Prevention of Type 2 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a Long-Standing Clinical Trial Incorporating Subjective and Objective Activity Measures
2020 · Andrea M. Kriska, Bonny Rockette-Wagner, et al. · Diabetes Care · 70
PDF
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma
2020 · David C. Smith, Matthias Kroiss, et al. · Investigational New Drugs · 61
Intravenous Glargine and Regular Insulin Have Similar Effects on Endogenous Glucose Output and Peripheral Activation/Deactivation Kinetic Profiles
2002 · Sunder Mudaliar, Pharis Mohideen, et al. · Diabetes Care · 38
PDF
Risk Factors for the Development of Retinopathy in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Experience
2022 · Neil H. White, Qing Pan, et al. · Diabetes Care · 34
PDF
A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia
2020 · Diala El-Maouche, Deborah P Merke, et al. · The Journal of Clinical Endocrinology & Metabolism · 34
The Diabetes Prevention Program and Its Outcomes Study: NIDDK’s Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact
2025 · Jill P. Crandall, Dana Dabelea, et al. · Diabetes Care · 28
PDF
Insulin and insulin-like growth factor-1 action on human skeletal muscle: Preferential effects of insulin-like growth factor-1 in type 2 diabetic subjects
2002 · Theodore P. Ciaraldi, Leslie Carter, et al. · Metabolism · 27
Association of Metformin With the Development of Age-Related Macular Degeneration
2022 · Amitha Domalpally, Samuel A. Whittier, et al. · JAMA Ophthalmology · 25
Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP)
2022 · Josephine H. Li, James A. Perry, et al. · Diabetes · 20
PDF
Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH
2023 · Josephine H. Li, Laura N. Brenner, et al. · Diabetologia · 19
PDF
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study
2012 · Christoph Beglinger, Ke Hu, et al. · Endocrine · 18
Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study
2002 · George E. Dailey, Pharis Mohideen, et al. · Clinical Therapeutics · 17
Prevalence of Distal Symmetrical Polyneuropathy by Diabetes Prevention Program Treatment Group, Diabetes Status, Duration of Diabetes, and Cumulative Glycemic Exposure
2024 · Christine G. Lee, Adam Ciarleglio, et al. · Diabetes Care · 10
PDF
The Metabolic Effects of Troglitazone in Patients with Diabetes and End-Stage Renal Disease
2005 · Pharis Mohideen, Michael Bornemann, et al. · Endocrine · 10
Works count: 48
Citation count: 2,213
H-index: 20
I10-index: 26
Year
Topic
Type